RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA
11 mars 2020 19h15 HE
|
Curium
Houston, TX and St. Louis, MO, March 11, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced the U.S. Food and Drug Administration (FDA) has granted copper Cu 64...
Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio
03 mars 2020 05h00 HE
|
Curium
St. Louis, MO, March 03, 2020 (GLOBE NEWSWIRE) -- Curium and DMH Worldwide have closed a transaction in which Curium has acquired Zevacor Molecular. Zevacor Molecular is a leader in the production...
Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.
13 nov. 2019 08h00 HE
|
Curium
St. Louis MO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Curium announced today that it intends to submit an abbreviated new drug application for a generic version of DaTscanTM (Ioflupane I 123 Injection) in...
Curium Announces Revised Pricing for Technescan MAG3TM
04 sept. 2019 08h30 HE
|
Curium
St. Louis, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Curium announced today that it is implementing a new pricing model for Technescan MAG3. Curium is phasing out its pay per dose sales model, in which...
Curium and RadioMedix Announce Exclusive Global Agreement for 64Cu-Dotatate Development
26 août 2018 21h00 HE
|
Curium
St. Louis and Houston, Aug. 26, 2018 (GLOBE NEWSWIRE) -- Curium and RadioMedix Inc. announce an exclusive agreement to develop and commercialize 64Cu-Dotatate, an investigational positron emission...
Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations
02 mai 2018 03h10 HE
|
Curium
Paris, May 02, 2018 (GLOBE NEWSWIRE) -- Curium has successfully completed its previously announced acquisition of the French commercial and manufacturing operations of Cyclopharma, a leading...